EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)

9 Months Ended

Sep. 30, 2017

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS [Abstract]

	Shares																Accumulated Deficit Attributable to Non-controlling			Accumulated Other Comp-
	Preferred								Preferred			Common		Accumulated			Interest in			rehensive			Equity
	Series F			Series G			Common		Stock			Stock		Deficit			Nutra SA			Loss			(Deficit)
Balance, December 31, 2016		-			-			10,790,351	$	-		$	264,232	$	(259,819	)	$	(699	)	$	(4,346	)	$	(632	)
Issuance of common stock awards under equity incentive plans		-			-			642,839		-			817		-			-			-			817
Dividend on preferred stock - beneficial conversion feature		-			-			-		-			778		(778	)		-			-			-
Modification of senior debenture holder warrants		-			-			-		-			582		-			-			-			582
Modification of subordinated note holder warrants		-			-			-		-			117		-			-			-			117
Change in classification of preferred stock to equity from liability		3,000			2,000			-		1,545			-		-			-			-			1,545
Change in classification of warrants to equity from liability		-			-			-		-			7,851		-			-			-			7,851
Conversion of preferred stock into common stock		(2,501	)		(700	)		2,331,627		(807	)		807		-			-			-			-
Proceeds from sale of common stock, net of costs		-			-			2,654,732		-			2,730		-			-			-			2,730
Exercise of warrant		-			-			103,008		-			101		-			-			-			101
Other		-			-			28,793		-			64		-			-			-			64
Proceeds from sale of membership interests		-			-			-		-			-		-			650			-			650
Foreign currency translation		-			-			-		-			-		-			38			93			131
Net loss		-			-			-		-			-		(205	)		(1,359	)		-			(1,564	)
Balance, September 30, 2017		499			1,300			16,551,350	$	738		$	278,079	$	(260,802	)	$	(1,370	)	$	(4,253	)	$	12,392

Summary of warrant activity

A summary of warrant activity for the nine months ended September 30, 2017, follows.

	Equity Warrants							Liability Warrants
	Shares Underlying			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Shares Underlying			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Outstanding, December 31, 2016		6,364,110		$	5.77		2.4		4,474,868		$	1.82		3.3
Issued		-		NA		NA			11,783,163			0.96		5.0
Impact of repricing debenture purchaser warrants:
Prior to repricing		(875,000	)		5.49		2.1		-		NA		NA
After repricing		875,000			0.96		5.5		-		NA		NA
Impact of repricing subordinated note holder warants:
Prior to repricing		(289,669	)		5.25		3.3		-		NA		NA
After repricing		289,669			0.96		3.3		-		NA		NA
Impact of anti-dilution clauses:
Prior to impact		-		NA		NA			(1,489,868	)		1.50		0.8
After impact		-		NA		NA			2,327,919			0.96		0.8
Transfer from liability to equity		14,468,163			1.16		4.8		(14,468,163	)		1.16		4.8
Exercised		-		NA		NA			(781,252	)		0.96		-
Forfeited, expired or cancelled		-		NA		NA			-		NA		NA
Outstanding, September 30, 2017		20,832,273		$	2.32		3.6		1,846,667		$	1.06		0.7
Exercisable, September 30, 2017		20,832,273		$	2.32		3.6		1,846,667		$	1.06		0.7

Summary of outstanding warrants

The following table summarizes information related to outstanding warrants as September 30, 2017 and December 31, 2016:

			September 30, 2017									December 31, 2016
Range of Exercise Prices		Type of Warrant	Shares Under Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)		Shares Under Warrants, Exercisable Cashless			Shares Under Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
										(4	)
$	0.96	Liability (1)		1,546,667	$	0.96		0.4		1,546,667			-	$	-		-
$	0.96	Equity		12,947,832		0.96		4.6		3,774,344			-		-		-
$	1.50	Liability (2)		300,000		1.60		2.9		300,000			-		-		-
$	1.50 to $1.60	Liability		-		-		-		-			1,789,868		1.52		1.3
$	2.00	Liability (3)		-		-		-		-			2,660,000		2.00		4.6
$	2.00	Equity		2,660,000		2.00		4.2		-			-		-		-
$	5.25	Liability (3)		-		-		-		-			25,000		5.25		3.6
$	5.25 to $5.87	Equity		3,156,670		5.33		2.2		359,536			4,296,339		5.36		2.7
$	6.55 to $16.80	Equity		2,067,771		6.61		1.5		190,899			2,067,771		6.61		2.0
				22,678,940	$	2.21		3.6		6,171,446			10,838,978	$	4.14		2.8

(1)

Includes one warrant which contains full ratchet anti-dilution provisions and is classified as derivative warrant liabilities in our balance sheet. Under the anti-dilution clause contained in this warrant, in the event of equity issuances (i.e. issuances of our common stock, certain awards of stock options to employees, and issuances of warrants and/or other convertible instruments) at prices below the exercise price of this warrant, we are required to lower the exercise price on this warrant and increase the number of shares underlying this warrant.

(2)

Includes a warrant to purchase of 300,000 shares of our common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant.

(3)

The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

(4)

Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of September 30, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details